CORRECTION article

Front. Immunol., 21 April 2022

Sec. Cancer Immunity and Immunotherapy

Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.887775

Corrigendum: Microbiome Crosstalk in Immunotherapy and Anti-Angiogenesis Therapy

  • 1. Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China

  • 2. Jiangsu Joint International Research Laboratory of Chinese Medicine and Regenerative Medicine, Nanjing, China

  • 3. Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China

  • 4. Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China

Article metrics

View details

1,4k

Views

756

Downloads

In the published article, there was an error in affiliation 3. Instead of “Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicine, China Pharmaceutical University, Nanjing, China”, it should be “Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

microbiome, immunotherapy, immune checkpoint, angiogenesis, prebiotics, Chinese medicine

Citation

Wan X, Song M, Wang A, Zhao Y, Wei Z and Lu Y (2022) Corrigendum: Microbiome Crosstalk in Immunotherapy and Anti-Angiogenesis Therapy. Front. Immunol. 13:887775. doi: 10.3389/fimmu.2022.887775

Received

02 March 2022

Accepted

01 April 2022

Published

21 April 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Yin Lu, ; Zhonghong Wei,

†These authors contributed equally to this work

This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics